July 28 Quick Takes: Spectrum gains on NSCLC data; plus Nabriva, Farxiga, Chi-Med, Merck-Lumos, BeiGene, Aerie, jCyte and moreBy BioCentury Staff

Spectrum therapy hits Phase II endpoint

Poziotinib met the prespecified primary endpoint in the ZENITH20 Phase II trial in previously treated non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertion mutations (Cohort 2), according to Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI). The company’s shares reached a high of $4.76 Tuesday before giving back some gains to finish at $3.65, up $0.41 (13%). ...